Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study.
about
Management of chemotherapy-induced nausea and vomiting by risk profile: role of netupitant/palonosetronA Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and VomitingTreatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and VomitingBiological and Pharmacological Aspects of the NK1-ReceptorNeurokinin-1 receptor antagonists in preventing postoperative nausea and vomiting: a systematic review and meta-analysisGaps in nutritional research among older adults with cancerRecent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive reviewDifference in the emetic control among highly emetogenic chemotherapy regimens: Implementation for appropriate use of aprepitantDelayed Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Incidence, and Current ManagementAPF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide-based highly emetogenic chemotherapy regimens: a post hoc subgroCheaper Options in the Prevention of Chemotherapy-Induced Nausea and Vomiting.Antiemetics: American Society of Clinical Oncology clinical practice guideline update.Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference.Update and new trends in antiemetic therapy: the continuing need for novel therapies.Review article: palliative care in gynecologic oncology.Management of chemotherapy-induced nausea and vomiting : focus on newer agents and new uses for older agents.Neuropharmacology and management of chemotherapy-induced nausea and vomiting in patients with breast cancer.Rolapitant for the treatment of chemotherapy-induced nausea and vomiting: a review of the clinical evidence.Chemotherapy-induced nausea and vomiting #285.An analysis of fosaprepitant-induced venous toxicity in patients receiving highly emetogenic chemotherapy.Aprepitant and fosaprepitant: a 10-year review of efficacy and safetyProphylactic treatment for delayed chemotherapy-induced nausea and vomiting after non-AC based moderately emetogenic chemotherapy: a systematic review of randomized controlled trialsResource Utilization for Chemotherapy-Induced Nausea and Vomiting Events in Patients with Solid Tumors Treated with Antiemetic RegimensChemotherapy-Induced Nausea and Vomiting: Time for More Emphasis on Nausea?Prevention of delayed nausea: a University of Rochester Cancer Center Community Clinical Oncology Program study of patients receiving chemotherapy.Effect of increase in duration of aprepitant consumption from 3 to 6 days on the prevention of nausea and vomiting in women receiving combination of anthracycline/cyclophosphamide chemotherapy: A randomized, crossover, clinical trial.Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial.A phase II, randomized study of aprepitant in the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapies in colorectal cancer patients.Comparison of the Control of Nausea and Vomiting among Several Moderately Emetic-Risk Chemotherapy Regimens.A Prospective, Randomized, Double-Blinded, Double-Dummy Pilot Study to Assess the Preemptive Effect of Triple Therapy with Aprepitant, Dexamethasone, and Promethazine versus Ondansetron, Dexamethasone and Promethazine on Reducing the Incidence of PoCost-effectiveness of an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer in the UKA randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy.Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy.Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy.Efficacy of triple antiemetic therapy (palonosetron, dexamethasone, aprepitant) for chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based, moderately emetogenic chemotherapy.Efficacy analysis of the aprepitant-combined antiemetic prophylaxis for non-round cell soft-tissue sarcoma patients received adriamycin and ifosfamide therapy.NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron.Combination of Aprepitant, Azasetron, and Dexamethasone as Antiemetic Prophylaxis in Women with Gynecologic Cancers Receiving Paclitaxel/Carboplatin Therapy.Differential pharmacology and clinical utility of rolapitant in chemotherapy-induced nausea and vomiting.Fosaprepitant-induced phlebitis: a focus on patients receiving doxorubicin/cyclophosphamide therapy.
P2860
Q26746211-55EA67DB-5EBD-4E68-AA9E-350218CA3411Q26784064-712F5368-AB2A-4396-904D-B2CA9133AA8FQ26784070-993E7736-8CFB-4A6B-95C0-B514046E5F17Q26784074-7900F26D-91D9-4F8E-9B00-AD00F56E8AD8Q26997344-BDE75F4A-1240-45EF-9AE0-0EC88625E07DQ28067552-99A1E116-A8EF-4715-8E29-09930C019416Q28081186-9FFEC666-C599-43A5-9174-BF785DEAA8D5Q28236344-83BEC84F-7A2F-43CC-B45B-51E14D088B03Q30235971-08866C1D-1E5D-4AEF-AF6D-05D338AE451EQ33734386-33EA8060-C5AC-4F63-B2EF-CBB811CAC18CQ33866119-8FBDDE42-623B-4DB7-A9DC-C1B62A1F8BC2Q34030613-BB67E241-AB08-4079-B736-9C9031C0B870Q34121232-75F50545-8493-4FDF-BDC0-3B6EB03DD919Q34143667-49C7F7B6-C304-42BF-AF6A-5564FD2DB2C2Q34156710-3521F875-82C3-47FF-828F-4C0EACD91DD4Q34327488-5F8B8E58-2A3C-4704-8AA0-F4BAFA2AADF5Q34403552-5DDEFC44-CCE0-42B9-8A81-F6D7F4D56E05Q34512212-1A0FDB2D-DBF9-485B-91CC-C02005E1017DQ34719140-1C7948AE-E580-4DE7-A7D8-B64399E2FA08Q35248313-4A5C21F6-646B-408E-A81C-322A546116F8Q35345557-E56D7403-100F-4A37-9F32-005C907A838FQ35789229-ABB5F597-B069-4518-AC5E-8E645FA1B21DQ36051908-A29F0310-C8AE-4F7F-9B35-D5E453F87544Q36064834-3350AF23-C9D5-4237-A692-1123AD0E96F8Q36222937-03E01EFF-7D09-45D5-8BEC-E615520F8E7AQ36357739-E4DD2BF1-4E38-4DEB-AD7A-D87EE6153E3FQ36384479-EEEE3F2A-70E7-448D-8C29-5996DEA296E4Q36640676-B5AD64E4-788E-4B79-BFA6-869A05A4977AQ36764931-71D434EE-08B9-49D4-B48A-B87D6CF424D5Q37063125-40047DA3-C0ED-4A94-9454-1C6A17A006AEQ37091366-CBBF319B-F16F-48C6-9156-832DA8C40C95Q37111164-D45DE247-E8BB-4A5D-BBED-55E84AE3F9C6Q37375653-1690ED5A-B700-4B44-BFC3-91D24E9451A6Q37452743-58506DAD-444B-46EF-AE63-F49CBD196E64Q37480802-782835B9-7C56-4BEA-8853-A3A3D01E4867Q37606033-906C4D51-B2E6-4CBE-A81B-3F6B231B4BEDQ37660556-CDBDC688-71DF-4B5D-9D85-4F7492319225Q37661865-29D15B29-6197-4A38-981D-BC2C7B8988D0Q37669043-09CAC62E-5C3A-47B1-BC98-2F4A6628FDDCQ37672351-B57DD56D-D3C1-435F-A608-001CE57C419C
P2860
Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Aprepitant for the prevention ...... andomized, double-blind study.
@en
Aprepitant for the prevention ...... andomized, double-blind study.
@nl
type
label
Aprepitant for the prevention ...... andomized, double-blind study.
@en
Aprepitant for the prevention ...... andomized, double-blind study.
@nl
prefLabel
Aprepitant for the prevention ...... andomized, double-blind study.
@en
Aprepitant for the prevention ...... andomized, double-blind study.
@nl
P2093
P1476
Aprepitant for the prevention ...... andomized, double-blind study.
@en
P2093
Alexandra Carides
Arlene Taylor
Carole Brown
Hans-Joachim Schmoll
James S Hardwick
Judith A Boice
Karin Jordan
Timothy Webb
P2888
P304
P356
10.1007/S00520-009-0680-9
P577
2009-07-01T00:00:00Z
P6179
1009268510